MX346206B - Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. - Google Patents
Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.Info
- Publication number
- MX346206B MX346206B MX2014000373A MX2014000373A MX346206B MX 346206 B MX346206 B MX 346206B MX 2014000373 A MX2014000373 A MX 2014000373A MX 2014000373 A MX2014000373 A MX 2014000373A MX 346206 B MX346206 B MX 346206B
- Authority
- MX
- Mexico
- Prior art keywords
- influenza
- group
- virus
- philogenetic
- viruses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161572417P | 2011-07-14 | 2011-07-14 | |
| EP11173953 | 2011-07-14 | ||
| PCT/EP2012/063637 WO2013007770A1 (en) | 2011-07-14 | 2012-07-12 | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000373A MX2014000373A (es) | 2014-03-31 |
| MX346206B true MX346206B (es) | 2017-03-09 |
Family
ID=47505543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000373A MX346206B (es) | 2011-07-14 | 2012-07-12 | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8961978B2 (https=) |
| EP (1) | EP2731967B1 (https=) |
| JP (1) | JP5683752B2 (https=) |
| KR (1) | KR101941724B1 (https=) |
| CN (1) | CN103906763B (https=) |
| AU (1) | AU2012282504B2 (https=) |
| BR (1) | BR112014000263B1 (https=) |
| CA (1) | CA2838999C (https=) |
| DK (1) | DK2731967T3 (https=) |
| EA (1) | EA027054B1 (https=) |
| ES (1) | ES2608321T3 (https=) |
| HR (1) | HRP20161740T1 (https=) |
| IL (1) | IL230222A (https=) |
| IN (1) | IN2014CN00953A (https=) |
| MX (1) | MX346206B (https=) |
| MY (1) | MY166282A (https=) |
| PH (1) | PH12013502479A1 (https=) |
| WO (1) | WO2013007770A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8961978B2 (en) | 2011-07-14 | 2015-02-24 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses |
| EP3566714A1 (en) | 2011-11-28 | 2019-11-13 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| MX367743B (es) | 2011-12-05 | 2019-09-04 | Trellis Bioscience Llc | Anticuerpos utiles para la inmunizacion pasiva de influenza. |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| MX387277B (es) | 2013-03-14 | 2025-03-12 | Contrafect Corp | Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada. |
| US9649375B2 (en) | 2013-03-14 | 2017-05-16 | The Administrators Of The Tulane Educational Fund | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
| KR20140118682A (ko) * | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| EA034639B1 (ru) | 2013-05-30 | 2020-03-02 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцины против вируса гриппа и их применения |
| SI3052192T1 (sl) | 2013-10-02 | 2020-11-30 | Medimmune, Llc | Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe |
| RU2682049C2 (ru) * | 2014-01-27 | 2019-03-14 | Дженентек, Инк. | Лечение вируса гриппа а h7n9 |
| US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| JP6712428B2 (ja) | 2014-02-04 | 2020-06-24 | コントラフェクト コーポレイション | インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法 |
| EP3105250B1 (en) | 2014-02-10 | 2020-08-05 | IGM Biosciences, Inc. | Iga multi-specific binding molecules |
| TW201620932A (zh) * | 2014-03-27 | 2016-06-16 | 建南德克公司 | 抗－ｂ型流感病毒血球凝集素抗體及其使用方法 |
| KR101628331B1 (ko) * | 2014-03-28 | 2016-06-08 | 주식회사 녹십자엠에스 | 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법 |
| MX378904B (es) | 2014-07-10 | 2025-03-10 | Janssen Vaccines & Prevention Bv | Vacunas para virus influenza y usos de las mismas. |
| EA035375B1 (ru) | 2014-07-10 | 2020-06-03 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцины против вируса гриппа и их применения |
| MX392761B (es) * | 2014-07-15 | 2025-03-21 | Medimmune Llc | Anticuerpos anti-influenza b neutralizantes y usos de los mismos. |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| MY186585A (en) | 2015-02-05 | 2021-07-28 | Janssen Vaccines & Prevention Bv | Binding molecules directed against influenza hemagglutinin and uses thereof |
| WO2016124682A1 (en) | 2015-02-05 | 2016-08-11 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza neuraminidase |
| KR102668588B1 (ko) * | 2015-04-08 | 2024-05-22 | 다나-파버 캔서 인스티튜트 인크. | 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법 |
| EP3294753A1 (en) | 2015-05-11 | 2018-03-21 | Janssen Vaccines & Prevention B.V. | Influenza virus neutralizing peptidomimetic compounds |
| EA201792500A1 (ru) | 2015-05-13 | 2018-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Aav-опосредованная экспрессия антител против гриппа и способы их использования |
| HUE056407T2 (hu) * | 2015-06-01 | 2022-02-28 | Medimmune Llc | Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik |
| EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| SG11201805001UA (en) * | 2016-01-13 | 2018-07-30 | Medimmune Llc | Method of treating influenza a |
| AU2017222564A1 (en) | 2016-02-24 | 2018-09-06 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| WO2017148889A1 (en) | 2016-03-01 | 2017-09-08 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza b neuraminidase |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| WO2018038096A1 (ja) * | 2016-08-23 | 2018-03-01 | 国立大学法人東京大学 | モノクローナル抗体又はその抗原結合フラグメント及びその使用 |
| AU2017350304B2 (en) | 2016-10-27 | 2022-03-03 | Janssen Vaccines & Prevention B.V. | Influenza virus neutralizing compounds |
| CA3051377A1 (en) * | 2017-01-27 | 2018-08-02 | National Research Council Of Canada | Hemagglutinin-specific antibodies and uses thereof |
| EP3577107A1 (en) | 2017-02-02 | 2019-12-11 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibition |
| WO2018141854A1 (en) | 2017-02-02 | 2018-08-09 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibition |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| UY37620A (es) | 2017-02-28 | 2018-08-31 | Univ Pennsylvania | Vacunas contra la gripe mediadas por aav novedosas |
| PT3589730T (pt) | 2017-02-28 | 2024-02-28 | Univ Pennsylvania | Vetor de vírus adenoassociado (aav) de clado f e suas utilizações |
| LT3743106T (lt) | 2018-01-23 | 2022-09-26 | Janssen Vaccines & Prevention B.V. | Gripo viruso vakcinos ir jų panaudojimo būdai |
| US11780907B2 (en) | 2018-01-26 | 2023-10-10 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
| US11230593B2 (en) | 2019-03-25 | 2022-01-25 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CA3152957A1 (en) * | 2019-09-05 | 2021-03-11 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| US11642407B2 (en) | 2020-02-28 | 2023-05-09 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
| WO2021201677A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting influenza |
| US11175293B1 (en) | 2021-01-04 | 2021-11-16 | University Of Utah Research Foundation | Rapid assay for detection of SARS-CoV-2 antibodies |
| US20240043416A1 (en) * | 2021-02-04 | 2024-02-08 | Sichuan Haisco Pharmaceutical Co., Ltd. | Salt and crystal form of ha inhibitor compound |
| WO2023201306A1 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | Compositions for preventing or treating influenza infections |
| CN120202213A (zh) | 2022-11-14 | 2025-06-24 | 扬森疫苗与预防有限公司 | 乙型流感病毒疫苗及其用途 |
| CN116589566A (zh) * | 2022-11-18 | 2023-08-15 | 昆明医科大学第一附属医院 | 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用 |
| WO2025051975A1 (en) | 2023-09-06 | 2025-03-13 | Sanofi | Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof |
| WO2026022067A1 (en) | 2024-07-20 | 2026-01-29 | Leyden Laboratories B.V. | Neutralising antibodies against influenza viruses |
| WO2026027730A1 (en) | 2024-07-31 | 2026-02-05 | Sanofi | Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof |
| WO2026052773A1 (en) | 2024-09-06 | 2026-03-12 | Sanofi | Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DK0934526T3 (da) | 1996-10-08 | 2003-05-05 | Bisys B V U | Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål |
| HK1048138B (zh) | 1999-04-15 | 2009-06-12 | 荷兰克鲁塞尔公司 | 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白 |
| ES2257560T3 (es) | 2001-06-15 | 2006-08-01 | Crucell Holland B.V. | Fagos quimericos. |
| EP2450377A1 (en) | 2006-09-07 | 2012-05-09 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof |
| FR2921928B1 (fr) * | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
| CA2731686C (en) | 2008-07-25 | 2020-04-07 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| EP2168987A1 (en) * | 2008-09-22 | 2010-03-31 | Mucosis B.V. | Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain |
| CA2761648C (en) | 2009-05-11 | 2019-03-12 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
| US8961978B2 (en) | 2011-07-14 | 2015-02-24 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses |
-
2012
- 2012-07-12 US US14/126,404 patent/US8961978B2/en active Active
- 2012-07-12 MX MX2014000373A patent/MX346206B/es active IP Right Grant
- 2012-07-12 IN IN953CHN2014 patent/IN2014CN00953A/en unknown
- 2012-07-12 JP JP2014519551A patent/JP5683752B2/ja active Active
- 2012-07-12 HR HRP20161740TT patent/HRP20161740T1/hr unknown
- 2012-07-12 AU AU2012282504A patent/AU2012282504B2/en active Active
- 2012-07-12 EP EP12735516.2A patent/EP2731967B1/en active Active
- 2012-07-12 EA EA201490288A patent/EA027054B1/ru not_active IP Right Cessation
- 2012-07-12 ES ES12735516.2T patent/ES2608321T3/es active Active
- 2012-07-12 CN CN201280034558.0A patent/CN103906763B/zh active Active
- 2012-07-12 BR BR112014000263-0A patent/BR112014000263B1/pt active IP Right Grant
- 2012-07-12 WO PCT/EP2012/063637 patent/WO2013007770A1/en not_active Ceased
- 2012-07-12 KR KR1020137035132A patent/KR101941724B1/ko active Active
- 2012-07-12 DK DK12735516.2T patent/DK2731967T3/en active
- 2012-07-12 MY MYPI2014700068A patent/MY166282A/en unknown
- 2012-07-12 PH PH1/2013/502479A patent/PH12013502479A1/en unknown
- 2012-07-12 CA CA2838999A patent/CA2838999C/en active Active
-
2013
- 2013-12-29 IL IL230222A patent/IL230222A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/597,016 patent/US9593159B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA027054B1 (ru) | 2017-06-30 |
| KR20140095017A (ko) | 2014-07-31 |
| MY166282A (en) | 2018-06-25 |
| US9593159B2 (en) | 2017-03-14 |
| WO2013007770A1 (en) | 2013-01-17 |
| CN103906763A (zh) | 2014-07-02 |
| US20150274811A1 (en) | 2015-10-01 |
| CA2838999A1 (en) | 2013-01-17 |
| JP5683752B2 (ja) | 2015-03-11 |
| BR112014000263A2 (pt) | 2017-02-14 |
| AU2012282504B2 (en) | 2017-07-20 |
| DK2731967T3 (en) | 2017-01-16 |
| EP2731967B1 (en) | 2016-10-12 |
| EP2731967A1 (en) | 2014-05-21 |
| ES2608321T3 (es) | 2017-04-07 |
| MX2014000373A (es) | 2014-03-31 |
| EA201490288A1 (ru) | 2014-05-30 |
| CA2838999C (en) | 2021-02-16 |
| CN103906763B (zh) | 2016-10-12 |
| US8961978B2 (en) | 2015-02-24 |
| KR101941724B1 (ko) | 2019-01-23 |
| BR112014000263B1 (pt) | 2022-01-18 |
| AU2012282504A1 (en) | 2014-02-06 |
| PH12013502479A1 (en) | 2014-01-20 |
| HRP20161740T1 (hr) | 2017-02-10 |
| JP2014527403A (ja) | 2014-10-16 |
| IL230222A (en) | 2017-09-28 |
| IN2014CN00953A (https=) | 2015-04-10 |
| US20140120113A1 (en) | 2014-05-01 |
| NZ618530A (en) | 2016-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014000373A (es) | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y el virus de influenza b. | |
| MX360056B (es) | Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos. | |
| MX2011011331A (es) | Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas. | |
| CY1124043T1 (el) | Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων | |
| MX2014000749A (es) | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| MD20140035A2 (ro) | Metodă de tratament al hepatitei virale C | |
| UY34701A (es) | Formas sólidas de un profármaco de nucleótidos de tiofosforamidato | |
| EA201590890A1 (ru) | Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу | |
| MX391051B (es) | Anticuerpos anti-cd47 y usos de los mismos. | |
| EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| MY175708A (en) | Dna antibody constructs and method of using same | |
| JO3204B1 (ar) | 4- أريل-n- فنيل-5،3،1- ترايازين-2- أمينات محتوية على مجموعة سلفوكسيمين | |
| EA201491412A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201590731A1 (ru) | Антитела к гемагглютинину и способы применения | |
| MX391043B (es) | Formulaciones de anticuerpo y metodos. | |
| CL2017002082A1 (es) | Nuevas proteínas especificas para pioverdina y pioquelina | |
| BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
| EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
| MX350282B (es) | Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas. | |
| MX387421B (es) | Producción de virus en huevos aviares. | |
| MX376962B (es) | Nuevos compuestos macrociclicos. | |
| MX378749B (es) | Agentes para neutralizacion de influenza. | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| EA201491581A1 (ru) | Везикулярные композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |